Developer docs
API playgroundTry for free, no card

Search company profiles

Retina Risk

Full company profile

uuid0004h3k

Namestring
Retina Risk
Legal namestring
RetinaRisk
Websiteurl
retinarisk.com
Company typeenum
Private
Founded yearint
2008
Short descriptiontext

RetinaRisk is an Icelandic health-IT company developing AI-driven diabetic retinopathy screening for U.S. primary care providers, using computer vision on retinal fundus images in a market reimbursed under Medicare CPT code 92229, though its operations appear dormant with a parked website.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersReykjavík, Iceland
HQ citystring
Reykjavík
HQ countrystring
Iceland
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
diabetic retinopathy screening, AI medical imaging, retinal diagnostic software, ophthalmology AI, autonomous AI diagnostics
Industry1 code
SECONDARYHLAKAKAN
Ocular Imaging & Diagnostic Testing Centers
NAICS code2 codes
  • Diagnostic Imaging Centers621512
  • Offices of Optometrists621320
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Optical Instruments & Lenses3827
Product category
AI-driven diabetic retinopathy screening
No data
GTM motion1 record

Each record includes

Type, Description, Source

Cost components3 values
Technology or R&D, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

RetinaRisk offers an AI-driven diabetic retinopathy screening solution that analyzes retinal fundus images using computer vision to detect signs of disease. The product enables autonomous AI diagnostics in primary care settings where access to ophthalmologists is limited, and is positioned as eligible for reimbursement under Medicare CPT code 92229. It targets healthcare providers serving the 38.4 million U.S. residents affected by diabetes.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • U.S. AI-driven diabetic retinopathy screening market projected to grow from USD 190.01M (2025) to USD 881.74M (2033) at 21.18% CAGR.
+1 more record
Product and service1 record
1RetinaRisk
CategoryAI-driven diabetic retinopathy screening
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Peers10 records
TypeDirect peer
Description

Eyenuk (EyeArt) is a leading FDA-cleared autonomous AI platform for diabetic retinopathy screening, directly competing in the same CPT 92229 reimbursed primary-care use case that Retina Risk targets.

TypeDirect peer
Description

Digital Diagnostics developed IDx-DR, the first FDA-authorized autonomous AI diagnostic system for diabetic retinopathy, and competes head-to-head with Retina Risk in primary-care screening.

TypeDirect peer
Description

AEYE Health offers FDA-cleared autonomous AI screening for diabetic retinopathy, targeting the same primary-care and U.S. market segment where Retina Risk is profiled.

TypeDirect peer
Description

IRIS provides AI-enabled retinal screening services to primary care, directly overlapping with Retina Risk's value proposition of bringing specialist-grade screening to non-ophthalmology settings.

TypeDirect peer
Description

Optomed combines handheld fundus cameras with AI screening software for diabetic retinopathy, operating in the same AI-driven screening category as Retina Risk.

TypeDirect peer
Description

RETINA-AI Health develops AI-based diabetic retinopathy screening tools explicitly named alongside Retina Risk in the U.S. market research, indicating overlapping customer and use-case focus.

TypeBroad incumbent
Description

Topcon is a global ophthalmic imaging incumbent whose fundus camera and AI screening ecosystem compete for the same diabetic retinopathy screening workflows targeted by Retina Risk.

8Carl Zeiss Meditec
TypeBroad incumbent
Description

Carl Zeiss Meditec is a major ophthalmic device and imaging incumbent with AI/retinal screening adjacencies, representing the broad established competitive backdrop for an AI DR screening vendor.

TypeBroad incumbent
Description

iCare, part of Revenio, produces retinal imaging devices and screening software, sitting in the same diabetic retinopathy ecosystem and explicitly named in Retina Risk's peer set.

TypeEmerging player
Description

BeamMed is named alongside Retina Risk in the U.S. AI diabetic retinopathy screening market, suggesting a comparable early-stage or niche AI screening profile.

Market position
Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Retina Risk

AI-driven diabetic retinopathy screeningretinarisk.com

RetinaRisk is an Icelandic health-IT company developing AI-driven diabetic retinopathy screening for U.S. primary care providers, using computer vision on retinal fundus images in a market reimbursed under Medicare CPT code 92229, though its operations appear dormant with a parked website.

Retina Risk firmographics

Firmographics
Name
Retina Risk
Legal name
RetinaRisk
Website
https://retinarisk.com
Company type
Private
Founded year
2008
Operating status
Closed
Headcount range
1–10 employees
Short description
RetinaRisk is an Icelandic health-IT company developing AI-driven diabetic retinopathy screening for U.S. primary care providers, using computer vision on retinal fundus images in a market reimbursed under Medicare CPT code 92229, though its operations appear dormant with a parked website.
Ownership category
akta.pro rank

Where Retina Risk is headquartered

Location

Headquarters

HQ city
Reykjavík
HQ country
Iceland
HQ region
Europe

Markets served

Retina Risk business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales

Go-to-market motion1 record

Retina Risk product offering

Product offering

Core offering

RetinaRisk offers an AI-driven diabetic retinopathy screening solution that analyzes retinal fundus images using computer vision to detect signs of disease. The product enables autonomous AI diagnostics in primary care settings where access to ophthalmologists is limited, and is positioned as eligible for reimbursement under Medicare CPT code 92229. It targets healthcare providers serving the 38.4 million U.S. residents affected by diabetes.

Differentiator

Problem solved

Functional benefit

Products and services

  • RetinaRisk

Quantifiable outcome

  • U.S. AI-driven diabetic retinopathy screening market projected to grow from USD 190.01M (2025) to USD 881.74M (2033) at 21.18% CAGR.
  • +1 more outcomes

Companies that use Retina Risk

Customer profile

Segments2 records

Ideal customer profiles1 record

Retina Risk technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature1 record

Retina Risk partnerships and signals

Strategic signal

Scale indicators3 records

Retina Risk competitors and assessment

Company assessment

Direct peers

  • Eyenuk: Eyenuk (EyeArt) is a leading FDA-cleared autonomous AI platform for diabetic retinopathy screening, directly competing in the same CPT 92229 reimbursed primary-care use case that Retina Risk targets.
  • Digital Diagnostics: Digital Diagnostics developed IDx-DR, the first FDA-authorized autonomous AI diagnostic system for diabetic retinopathy, and competes head-to-head with Retina Risk in primary-care screening.
  • AEYE Health: AEYE Health offers FDA-cleared autonomous AI screening for diabetic retinopathy, targeting the same primary-care and U.S. market segment where Retina Risk is profiled.
  • IRIS (Intelligent Retinal Imaging Systems): IRIS provides AI-enabled retinal screening services to primary care, directly overlapping with Retina Risk's value proposition of bringing specialist-grade screening to non-ophthalmology settings.
  • Optomed: Optomed combines handheld fundus cameras with AI screening software for diabetic retinopathy, operating in the same AI-driven screening category as Retina Risk.
  • RETINA-AI Health: RETINA-AI Health develops AI-based diabetic retinopathy screening tools explicitly named alongside Retina Risk in the U.S. market research, indicating overlapping customer and use-case focus.

Broad incumbents

  • Topcon Healthcare: Topcon is a global ophthalmic imaging incumbent whose fundus camera and AI screening ecosystem compete for the same diabetic retinopathy screening workflows targeted by Retina Risk.
  • Carl Zeiss Meditec: Carl Zeiss Meditec is a major ophthalmic device and imaging incumbent with AI/retinal screening adjacencies, representing the broad established competitive backdrop for an AI DR screening vendor.
  • iCare (Revenio Group): iCare, part of Revenio, produces retinal imaging devices and screening software, sitting in the same diabetic retinopathy ecosystem and explicitly named in Retina Risk's peer set.

Emerging players

  • BeamMed: BeamMed is named alongside Retina Risk in the U.S. AI diabetic retinopathy screening market, suggesting a comparable early-stage or niche AI screening profile.

Market position

Customer concentration

Retina Risk financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Retina Risk leadership team

Management profile

Number of profiles

Profiles6 records

Retina Risk funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Retina Risk M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Retina Risk

What does Retina Risk do?

RetinaRisk offers an AI-driven diabetic retinopathy screening solution that analyzes retinal fundus images using computer vision to detect signs of disease. The product enables autonomous AI diagnostics in primary care settings where access to ophthalmologists is limited, and is positioned as eligible for reimbursement under Medicare CPT code 92229. It targets healthcare providers serving the 38.4 million U.S. residents affected by diabetes.

Is Retina Risk a public or private company?

Retina Risk is a private company. It is classified as founder individual operated bootstrapped and is currently closed.

When was Retina Risk founded?

Retina Risk was founded in 2008. It employs 1 to 10 people.

Where is Retina Risk based?

Retina Risk is headquartered in Reykjavík, Iceland, in the Europe region.

Who are Retina Risk's main competitors?

Direct peers on record are Eyenuk, Digital Diagnostics, AEYE Health, IRIS (Intelligent Retinal Imaging Systems), Optomed and RETINA-AI Health. Broad incumbents are Topcon Healthcare, Carl Zeiss Meditec and iCare (Revenio Group). BeamMed is listed as an emerging player.

Does Retina Risk have an API?

No public API is recorded for Retina Risk.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales